Imaged-based Diagnostic to detect eligible lung cancer patients to receive Targeted therapy

PreciousMD是由法特梅·阿梅里博士于2019年在伦敦创立的女性领导和女性主导的公司。在PreciousMD，我们正在开发一种辅助诊断方法，以确定哪些肺癌患者可以从接受表皮生长因子受体(EGFR)抑制药物(即靶向治疗)中受益。在世界范围内，肺癌是最常见的诊断癌症，仍然是癌症发病率和死亡率的主要原因，每年有210万新发肺癌病例和180万人死亡，占癌症死亡人数的近五分之一(18.4%)。在欧洲，每年约有32万人被诊断为肺癌，复发率为50%，存活率仅为12%。抑制EGFR的药物证明了肺癌患者的长期生存，然而，并不是每个人都有资格。候选不是通过癌症的类型来确定的，而是通过EGFR基因突变的存在来确定的。因此，在推荐靶向治疗之前，检测EGFR突变是必不可少的。我们开发的核心技术证实了我们方法的有效性。我们现在正处于关键时刻，我们需要对我们的技术进行关键的临床验证。为了实现这一点，我们需要一个平台，让我们能够向专家展示我们的创新。经过我们的研究，我们得出的结论是，能够展示我们的算法的基于网络的软件套件将是最有效的前进方式。这为在临床环境中验证我们的技术提供了基础。这笔赠款将使我们能够开发和维护该软件套件。像我们这样的医疗科技公司需要比常规技术公司甚至深度技术公司更多的时间和资金来增长，因为我们需要获得监管部门的批准，这可能非常漫长和昂贵。非赠款一揽子支持计划为我们提供了一个与投资欧盟和欧洲企业网络接触的机会，这些网络、指导和投资为我们提供了成长和服务癌症患者所需的正确网络、指导和投资

PreciousMD is female led and female dominated company found by Dr. Fatemeh Ameri in 2019 in London. At PreciousMD, we are developing a companion diagnostic to identify lung cancer pa-tients who can benefit from receiving epidermal-growth-factor receptor (EGFR) inhibi-ting drugs (i.e. targeted therapy). Worldwide, lung cancer is the most commonly diagnosed cancer and remains the leading cause of cancer incidence and mortality, with 2.1 million new lung cancer cases and 1.8 million deaths annually; representing close to 1 in 5 (18.4%) cancer deaths. In Europe about 320,000 people are diagnosed with the lung cancer annually, with 50% recur-rence and only a 12% survival rate. EGFR-inhibiting drugs demonstrated long-term survival for lung cancer patients, however, not everybody is eligible. The candidates are identified not by the type of cancer, but by the presence of EGFR-gene mutations. Therefore, detection of EGFR-mutation is essential before targeted therapy can be recommended. We developed our core technology that confirms the validity of our approach. We are now at a critical juncture where we need crucial clinical validation on our technology. To achieve this, we need a platform to enable us present our innovation to the experts. Having done our research, we have concluded that a web-based software suite capable of showcasing our algorithms would be the most effective way forward. This provides the foundation for validating our technology in clinical setting. This grant will enable us to develop and maintain this software suite. MedTech companies like us require more time and capital to grow than regular tech and even deep techs, because we need to get the regulatory approvals which can be extremely long and costly. The non-grant package of support provides us with an opportunity to engage with the Invest EU and Enterprise Europe Network which provide us with the right network, mentorship and investment we need to grow and serve cancer patients